Primary cutaneous follicle center lymphoma with diffuse CD30 expression: A report of 4 cases of a rare variant  

Oleh:

Kempf, Werner ; Kazakov, Dmitry V. ; Rutten, Arno ; Rupec, Rudolf A. ; Talarcik, Petr

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: JAAD: Journal of the American Academy of Dermatology (keterangan: ada di ClinicalKey) vol. 71 no. 03 (Sep. 2014), page 548–554 .
Topik: CD30; cutaneous lymphoma; diffuse large B-cell lymphoma; follicular lymphoma; Gorlin–Goltz syndrome; PTCH

Ketersediaan

Perpustakaan FK Nomor Panggil: J15.K Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Background CD30 is expressed in aggressive and Epstein–Barr virus–associated forms of B-cell non-Hodgkin lymphomas, but is rarely expressed by the majority of tumor cells in primary cutaneous B-cell lymphomas (CBCLs). The expression of CD30 in CBCLs may be at risk for misinterpretation as an unequivocal indicator of a highly aggressive form of the disease. Objective We report 4 cases of low malignant primary cutaneous follicle center lymphoma (PCFCL) with diffuse and strong expression of CD30 by the majority of neoplastic cells. Results The patients included 3 men and 1 woman with tumors on the scalp (3 patients) and chest wall (1 patient). The histologic examinations revealed a mixed, diffuse, and follicular growth pattern with CD20+, bcl-6+, and bcl-2- tumor cells. Seventy percent to 90% of the tumor cells expressed CD30. Clonal rearrangement of immunoglobulin heavy chain genes was found in 1 of 4 cases. None of the 3 cases yielded positivity for Epstein–Barr virus RNA. Limitations The study is limited by the small number of patients. Conclusions This rare variant of CD30+ PCFCL needs be distinguished from CD30+ aggressive B-cell lymphomas. CD30 in this variant of CBCLs may serve as a therapeutic target for anti-CD30 antibody–based strategies.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali